Qiang Zhao
Director/Board Member bij Shanghai Haihe Biopharma Co., Ltd.
Profiel
Qiang Zhao is an Independent Director at Shanghai Haihe Biopharma Co., Ltd.
since 2020.
Prior to this, he held the position of Independent Director at Jionto Energy Investment Co., Ltd.
Hebei.
He also served as an Independent Director at Beijing Chieftain Control Engineering Technology Co., Ltd.
from 2017 to 2023.
Actieve functies van Qiang Zhao
Bedrijven | Functie | Begin |
---|---|---|
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Director/Board Member | 08-09-2020 |
Eerdere bekende functies van Qiang Zhao
Bedrijven | Functie | Einde |
---|---|---|
BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Director/Board Member | 10-06-2023 |
JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Director/Board Member | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
JOINTO ENERGY INVESTMENT CO., LTD. HEBEI | Utilities |
BEIJING CHIEFTAIN CONTROL ENGINEERING TECHNOLOGY CO., LTD. | Producer Manufacturing |
Bedrijven in privébezit | 1 |
---|---|
Shanghai Haihe Biopharma Co., Ltd.
Shanghai Haihe Biopharma Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shanghai Haihe Biopharma Co., Ltd engages in the development, production, and sale of anti-tumor innovative drugs. It focuses on new anti-tumor drug projects, providing cancer therapies, and development of anti-tumor drugs such as oral paclitaxel, tyrosine kinase inhibitors, PI3Ka inhibitors, and Glumetinib. The company was founded on March 11, 2011 and is headquartered in Shanghai, China. | Commercial Services |